Partnership with Us

2025/09/15 Mycenax and SPERA PHARMA Forge Strategic Alliance to Streamline ADC Drug Substance and Drug Product Manufacturing Services

 

---

 

2025/08/12 [Merck's Webinar] Upstream Intensification in Action: From CLD to PD with Real-World Insights

 

---

 

2025/07/22 Exclusive Seminar & Facility Tour: Aseptic Fill-Finish in Focus

 

---

 

2025/06/16 Mycenax Granted Exclusive Rights to RIN Institute's Proprietary ADC Linker Patents for CDMO Services

 

 

---

 

 

2025/05/26 Mycenax, Kidswell Bio and Chiome Bioscience Enter into Master Service Agreement for Development of New Biosimilar Drugs

 

 

---

 

 

2025/05/22 Mycenax Partners to Establish Japan's Domestic Biosimilar Manufacturing Facilities

 

 

---

 

2025/04/23 Mycenax Open House on April 23, 2025

 

 

---

 

 

2025/03/07 Mycenax and Sartorius Join Forces to Enhance Biopharmaceutical Manufacturing Solutions

 

 

---

 

 

2024/11/28 Mycenax and Apexcella collaborate to Advance Commercialization of Allogeneic Natural Killer Cell Therapies to Benefiting More Patients

 

 

---

 

 

2024/06/24 MYCENAX and CHITOSE Join Forces to Forge a New Era of Cell Line Development

 

 

---

 

 

2024/01/24 Merck Signs MoU with Mycenax Biotech to Drive Innovation in Bioprocessing Technology

 

 

 

---

 

 

2022/09/21 Mycenax signs MoU with KriSan Biotech: Building ADC Industry Value Chain

 

 

---

 

2021/08/26 Mycenax and Cytiva Enable First Continuous Manufacturing Process Development Satellite Laboratory in Taiwan

 

---

2021/06/08 Mycenax signs an MOU with CHO PHARMA, cooperating to expand the production and application of next-generation antibodies

 

---

 

2021/05/28 Mycenax becomes Taiwan’s first CDMO company to complete the CHO-S and CHOZN® GS Cell Line Development with the Beacon® Optofluidic System